Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “roflumilast”

29 pharma patents match "roflumilast" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 29
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 29 pharmaceutical patents matching "roflumilast" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

29 results for “roflumilast” · 30,257 patents in full index Clear search

  1. US 12336983

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  2. US 12329751

    Topical roflumilast formulation having antifungal properties

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  3. US 12310956

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  4. US 12257242

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  5. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  6. US 12144802

    Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  7. US 12042558

    Method and formulation for improving roflumilast skin penetration lag time

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  8. US 12016848

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  9. US 12011437

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  10. US 12005052

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  11. US 12005051

    Topical roflumilast formulation having improved delivery and plasma half life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  12. US 11819496

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  13. US 11793796

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  14. US 11707454

    Topical roflumilast formulation having antifungal properties

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  15. US 11534493

    Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Dec 27, 2022 · Expires Dec 22, 2042

    granted
  16. US 11129818

    Topical roflumilast formulation having improved delivery and plasma half life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted
  17. US 10940142

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted
  18. US 10172841

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  19. US 10105354

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  20. US 9907788

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted
  21. US 9895359

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  22. US 9884050

    Inhibition of crystal growth of roflumilast

    Arcutis, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  23. US 9205044

    Aqueous pharmaceutical preparation comprising roflumilast

    TAKEDA GMBH · Granted Dec 8, 2015 · Expires Dec 3, 2035

    granted
  24. US 8663694

    Taste masked dosage form containing roflumilast

    TAKEDA GMBH · Granted Mar 4, 2014 · Expires Feb 27, 2034

    granted